A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.
Frontiers in pediatrics（2023）
摘要
ClinicalTrials.gov: NCT02756845. https://clinicaltrials.gov/ct2/show/NCT02756845.
更多查看译文
关键词
immunotherapy, pediatric solid tumor, talimogene laherparepvec, non-CNS tumors, relapsed and refractory cancer, oncolytic herpes virus
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要